A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing the importance of comprehensive biomarker testing at diagnosis rather than piecemeal testing.
Video content above is prompted by the following:
Role of Folate Receptor Alpha Testing
Mirvetuximab soravtansine, an antibody-drug conjugate targeting FRα, represents the newest approved therapy in ovarian cancer. Testing considerations include the following:
The NCCN recommends universal FRα testing as part of comprehensive biomarker assessment, which has shifted from individual tests to comprehensive panels performed at diagnosis.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More